Infusions of antibody-laden blood have been used with reported success in prior outbreaks, including the SARS epidemic and the 1918 flu pandemic
Infusions of antibody-laden blood have been used with reported success in prior outbreaks, including the SARS epidemic and the 1918 flu pandemic
With a vaccine for COVID-19 still a long way from being realized, Johns Hopkins immunologist Arturo Casadevall is working to revive a century-old blood-derived treatment for use in the United States in hopes of slowing the spread of the disease.
With the right pieces in place, the treatment could be set up at Johns Hopkins University in Baltimore within a matter of weeks, Casadevall says.
The technique uses antibodies from the blood plasma or serum of people who have recovered from COVID-19 infection to boost the immunity of newly infected patients and those at risk of contracting the disease. These antibodies contained in the blood’s serum have the ability to bind to and neutralize SARS-CoV-2, the virus that causes COVID-19. Casadevall—a Bloomberg Distinguished Professor of molecular microbiology and immunology and infectious diseases at the Johns Hopkins Bloomberg School of Public Health and School of Medicine—published a paper on the proposal today in The Journal of Clinical Investigation.
“Deployment of this option requires no research or development,” he says. “It could be deployed within a couple of weeks since it relies on standard blood-banking practices.”
“DEPLOYMENT OF THIS OPTION REQUIRES NO RESEARCH OR DEVELOPMENT. IT COULD BE DEPLOYED WITHIN A COUPLE OF WEEKS SINCE IT RELIES ON STANDARD BLOOD-BANKING PRACTICES.”
Arturo Casadevall
The medical concept—known as “convalescent plasma” or “convalescent sera”—dates back to the early 20th century, and was used successfully in the past to counter epidemics including mumps and the measles. In a recent Wall Street Journal op-ed, Casadevall points to a notable case preventing a measles outbreak at a U.S. prep school in 1934.
Experts say a challenge of the technique is that precise timing is important in order to maximize the boost to a patient’s immunity. The treatment is not envisioned as a panacea to treating coronavirus, but a temporary measure that could help until stronger options such as vaccines are available.
“It’s all doable—but to get it done it requires effort organization, resources… and people who have recovered from the disease who can donate the blood,” Casadevall says. He adds that many people have stepped up to the plate at Hopkins and are already working to put this system in place.
Casadevall says he believes the solution “could do a lot locally” in the Baltimore region. He also noted that Johns Hopkins could become the Investigational New Drug (IND) center in the U.S. for this treatment, helping to administer it across states.
Learning more about how to use the sera most effectively will require further clinical studies. “We will learn new science from this calamity,” Casadevall says.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Covid-19 treatment
- Global Veterinary Pain Management Market (2021 to 2026) - Growth, Trends, COVID-19 Impact, and Forecastson April 15, 2021 at 4:58 am
The "Veterinary Pain Management Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering. The Veterinary Pain management market ...
- The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Spliton April 15, 2021 at 4:56 am
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) ...
- Measures to curb Covid-19 surge a collective effort: NTF adviseron April 15, 2021 at 4:24 am
The spike in coronavirus cases is not unique to the Philippines.This fact was emphasized by National Task Force (NTF) Against Covid-19 medical adviser Dr. Teddy Herbosa during the Palace briefing on ...
- Only four COVID-19 patients under treatment in Hai Duong hotspoton April 15, 2021 at 4:05 am
VOV.VN - The northern province of Hai Duong, the country’s biggest coronavirus hotspot, has gone through three weeks without new locally transmitted coronavirus cases, and 722 out of 726 positive ...
- 1,701 Covid-19 cases detected at Haridwar Kumbh Mela in past 5 dayson April 15, 2021 at 3:56 am
At least 1,701 people have tested positive for Covid-19 in the past five days at the Haridwar Kumbh Mela. People are attending the Kumbh Mela in lakhs and are seen openly flouting Covid-19 protocol.
Go deeper with Google Headlines on:
Covid-19 treatment
Go deeper with Bing News on:
Covid-19
- Africa CDC says cannot predict when second COVID-19 shots will arriveon April 15, 2021 at 4:48 am
Many Africans who have received their first COVID-19 vaccine do not know when they will get a second shot because deliveries are delayed, the continent's top public health official said on Thursday.
- Ivanka Trump's Instagram account was flooded with angry comments after she posted photos of herself getting a COVID-19 vaccineon April 15, 2021 at 4:37 am
Ivanka Trump posted photos of herself getting the Pfizer shot in Florida, and encouraged her followers to get vaccinated too.
- This SF man's grandmother couldn't find a COVID-19 vaccine. So he made a Twitter bot to help.on April 15, 2021 at 4:09 am
The man behind these accounts is Omar Darwish, a senior security engineer at the San Francisco identity service management company Okta. His inspiration came from the difficulty his family in Texas ...
- Merck plans large outpatient trial of COVID-19 pill, stops study in hospitalized patientson April 15, 2021 at 4:05 am
Merck & Co Inc on Thursday said it plans a large study of what could become the first pill to target the coronavirus in people at risk of severe COVID-19, but will no longer pursue use of the ...
- Study shows vaccines carry much lower risk of blood clots than COVID-19on April 15, 2021 at 4:03 am
Research by Oxford University suggests all major vaccines carry a similar risk of rare clots, and all seem to have much lower risk than infection with COVID-19.